View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Study-AMLSG - Daunorubicin 50 / Cytarabine 500, Acute Myeloid Leukemia, Induction II, over 60 years of age
Protocol-ID: 1812 V1.0 (Mini), STUDY-AMLSG-DAUN50/CYTA500, AML Ind. II, over 60Indication(s)
- Acute Myeloid Leukemia; ICD-10 C92.0-, C92.5-, C93.0-, C92.8-, C92.6-, C92.7-, C92.9-
Links
- Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics [clinicaltrials.gov]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 25.07.2021